Monopar Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: MNPR · Form: 8-K · Filed: Jun 23, 2025 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Jun 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance, filing
TL;DR
Monopar Therapeutics is holding a shareholder vote on June 17th. Details to follow.
AI Summary
Monopar Therapeutics Inc. filed an 8-K on June 23, 2025, reporting a submission of matters to a vote of security holders on June 17, 2025. The company, incorporated in Delaware, is involved in the pharmaceutical preparations industry and is headquartered in Wilmette, Illinois.
Why It Matters
This filing indicates that Monopar Therapeutics is seeking approval from its shareholders on specific corporate actions, which could impact the company's future direction and governance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not indicating any immediate financial distress or significant operational change.
Key Numbers
- 001-39070 — SEC File Number (Identifies the company's filing history with the SEC.)
- 32-0463781 — I.R.S. Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- June 17, 2025 (date) — Date of earliest event reported
- June 23, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Wilmette, IL (location) — Principal executive offices
FAQ
What specific matters are being submitted for a vote of security holders?
The filing states 'Submission of Matters to a Vote of Security Holders' as the item information, but the specific details of these matters are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 17, 2025.
What is the principal business of Monopar Therapeutics?
Monopar Therapeutics is in the 'PHARMACEUTICAL PREPARATIONS' industry, SIC code 2834.
Where are Monopar Therapeutics' principal executive offices located?
The principal executive offices are located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
What is the trading symbol for Monopar Therapeutics' securities?
The excerpt mentions 'Trading Symbol(s)' but does not list the specific symbol for Monopar Therapeutics.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 23, 2025 regarding Monopar Therapeutics (MNPR).